Publication details
Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Journal of blood medicine |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.2147/JBM.S64067 |
| Field | Oncology and hematology |
| Keywords | decitabine; acute myeloid leukemia; prognosis; leukemia; adult |
| Description | Background: In a Phase III trial, 485 patients ($65 years) with newly diagnosed acute myeloid leukemia received decitabine 20 mg/m2 intravenously for 5 days every 4 weeks or a treatment choice (supportive care or cytarabine 20 mg/m2 subcutaneously for 10 days every 4 weeks). Materials and methods: We summarized overall and progression-free survival by baseline white blood cell count using two analyses: ,1, 1–5, .5×109/L; #10 or .10×109/L. Results: There were 446 deaths (treatment choice, n=227; decitabine, n=219). Median overall survival was 5.0 (treatment choice) versus 7.7 months (decitabine; nominal P=0.037). Overall survival differences between white blood cell groups were not significant; hazard ratios (HRs) favored decitabine. Significant progression-free survival differences favored decitabine for groups 1–5×109/L (P=0.005, HR =0.67), greater than 5×109/L (P=0.027, HR =0.71), and up to 10×109/L (P=0.003, HR =0.72). Conclusion: There was a trend toward improved outcome with decitabine, regardless of baseline white blood cell count. |